[
  {
    "ts": null,
    "headline": "Insulet : 2024 EEO-1 Report",
    "summary": "‌2024 Consolidated EEO-1 This report reflects Insulet's U.S. workforce data as of December 31, 2024. The use of specific job categories aligns with the U.S. Equal Employment...",
    "url": "https://finnhub.io/api/news?id=b25cf1e6ce5da882f2810993bdd73f85f861b08127037987562df7ab26ae7f7a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751283019,
      "headline": "Insulet : 2024 EEO-1 Report",
      "id": 135654341,
      "image": "",
      "related": "PODD",
      "source": "Finnhub",
      "summary": "‌2024 Consolidated EEO-1 This report reflects Insulet's U.S. workforce data as of December 31, 2024. The use of specific job categories aligns with the U.S. Equal Employment...",
      "url": "https://finnhub.io/api/news?id=b25cf1e6ce5da882f2810993bdd73f85f861b08127037987562df7ab26ae7f7a"
    }
  },
  {
    "ts": null,
    "headline": "5 Insightful Analyst Questions From Insulet’s Q1 Earnings Call",
    "summary": "Insulet’s first quarter was marked by strong momentum, as the company delivered results that exceeded Wall Street’s expectations and were met with a positive market reaction. Management attributed this outperformance to robust demand for its Omnipod 5 insulin delivery system, particularly in both U.S. and international markets. CEO Ashley McEvoy, newly appointed to the role, emphasized the company’s success in attracting new users, noting that more than 30% of U.S. new customer starts were from",
    "url": "https://finnhub.io/api/news?id=536c95ee755febf1c35870b8a3bca5e04e74e7b573049c1dbd39342a62a715f5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751278770,
      "headline": "5 Insightful Analyst Questions From Insulet’s Q1 Earnings Call",
      "id": 135672268,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PODD",
      "source": "Yahoo",
      "summary": "Insulet’s first quarter was marked by strong momentum, as the company delivered results that exceeded Wall Street’s expectations and were met with a positive market reaction. Management attributed this outperformance to robust demand for its Omnipod 5 insulin delivery system, particularly in both U.S. and international markets. CEO Ashley McEvoy, newly appointed to the role, emphasized the company’s success in attracting new users, noting that more than 30% of U.S. new customer starts were from",
      "url": "https://finnhub.io/api/news?id=536c95ee755febf1c35870b8a3bca5e04e74e7b573049c1dbd39342a62a715f5"
    }
  }
]